Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Send this study to a contact
1
Your personal information
Your name
Your e-mail
Send me a copy
2
Your recipient's information
The name of your contact
Your contact email
3
Your message
Votre message
Efficacy and safety of Symbicort® Turbuhaler® 160/4.5 µg/inhalation, two inhalations twice daily plus as-needed compared with Seretide™ Diskus™ 50/500 µg/inhalation, one inhalation twice daily plus terbutaline Turbuhaler 0.4 mg/inhalation as-needed - a 6-month randomised, double-blind, parallel-group, active controlled, multinational phase IIIB study in adult and adolescent patients with persistent asthma https://kusajili.com:443/Trial/GOGeamLpbEG_yZcln8i-hQ%24efficacy-and-safety-of-symbicortr-turbuhalerr-16045-ginhalation-two-inhalations-twice-daily-plus-as-needed-compared-with-sereti
I have read and accept the terms of use of the site and the Privacy Policy
Send your message